Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: A non-randomized prospective study

Virology Journal

Volumn 2, Issue , 2005, Pages

  Kamara, Paul ^a   Melendez Guerrero, Loyda ^b   Arroyo, Miguel ^c   Weiss, Heidi ^d   Jolly, Pauline ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEUTRALIZING ANTIBODY; NEVIRAPINE; STAVUDINE; VIRUS ANTIBODY; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE TRANSMISSION; ENHANCER REGION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MACROPHAGE; MATERNAL PLASMA; MULTIVARIATE ANALYSIS; NEWBORN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PUERTO RICO; STATISTICAL SIGNIFICANCE; VERTICAL TRANSMISSION; VIRUS ENVELOPE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIGENS, VIRAL; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MULTIVARIATE ANALYSIS; NEUTRALIZATION TESTS; ODDS RATIO; PREGNANCY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 17844406387     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-2-15     Document Type: Article

References (58)

1. UNAIDS: Report on the global HIV/AIDS epidemic: Joint United Nations Programme on HIV/AIDS 2004.
2. Centers for Disease Control and Prevention (CDC): Administration of zidovudine during late pregnancy and delivery to prevent peri-natal HIV transmission - Thailand, 1996-1998. Morb Mortal Wkly Rep 1998, 47:151-4.
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, Sullivan MJ, Van Dyke R, Bey M, Shearer W, Jacobson R, Jimenez E, O'Neill E, Bazin B, Delfraissy JF, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New Eng J Med 1994, 331:1173-1180.
4. Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomised Trial. Lancet 1999, 354:795-802.
5. US Department of Health and Human Services: Researchers identify a simple, affordable drug regimen that is highly effective in preventing HIV infection in infants of mothers with the disease. HHS News . July 14, 1999
6. Hengel RL, Kennedy MS, Steketee RW, Thea DM, Abrams EJ, Lambert G, McDougal JS, the New York City Perinatal HIV Transmission Collaborative Study Group: Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. AIDS Res Human Retrovir 1998, 14:475-481.
7. Mabondzo A, Rouvier P, Raoul H, Le Naour R, Courpotin C, Herve F, Parnet-Mathieu F, Lasfargues G, Dormont D: Relationship between humoral factors in HIV-1-infected mothers and the occurrence of HIV infection in their infants. Clin Exp Immunol 1995, 102:476-480.
8. Scarlatti G, Albert G, Rossi P, Hodara V, Biraghi P, Muggiasca L, Fenyo EM: Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993, 168:207-10.
9. Ugen KE, Goedert JJ, Boyer J, Rafaeli Y, Frank I, Williams WV, Willoughby A, Landesman S, Mandez H, Rubinstein A, Kieber-Emmons T, Weiner DB: Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera glycoprotein 120 and 41 peptides from HIV Type 1. J Clin Invest 1992, 89:923-1930.
10. Khouri YF, MacIntosh K, Cavacini L, Posner M, Pagano M, Tuomala R, Marasco WA: Vertical transmission of HIV-1. correlation with maternal viral load and plasma levels of CD4 binding site anti-gp 120 antobodies. J Clin Invest 1995, 95:732-737.
11. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A: Vertical transmission of human Immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci 1990, 87:3445-3449.
12. Rossi P, Moschese V, Broliden PA, Fundaro C, Plebani A, Giaquinto C, Tovo PA, Ljunggren K, Rosen J, Wigzell H, Jonda M, Wharen B: Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci USA 1989, 86:8055-8.
13. Erb P, Krauchi S, Burgin D, Biederman K, Camli C, Rudin CH, the Swiss HIV and Pregnancy Collaborative Study Group: Quantitative anti-p24 determinations can predict the risk of vertical transmission. J AIDS 1994, 7:261-4.
14. Kliks SC, Levy JA: Maternal antibody response and maternal-infant HIV-1 transmission [letter; comment]. Lancet 1994, 343:1364.
15. Scarlatti G, Leitner T, Hodara V, Halapi E, Rossi P, Albert J, Fenyo EM: Neutralizing antibodies and viral characteristics in motherto-child transmission of HIV-1. AIDS 1993, 7(suppl 2):S45-S48.
16. St Louis ME, Pau CP, Msuami M, Ou CY, Matela B, Kashamuka M, Brown C, George JR, Heyward WL: Lack of association between anti-V3 loop antibody and perinatal HIV-1 transmission in Kinshasa, Zaire, despite use of assays based on local HIV-1 strains. J Acq Immun Defic Synd 1994, 7:63-67.
17. Lallemant M, Baillou A, Lallemant-LeCoeur S, Nzingoula S, Mampaka M, M'Pele P, Barin F, Essex M: Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 1994, 343:1001-1005.
18. O'Shea S, Newell ML, Dunn DT, Garcia-Rodriguez MC, Bates I, Mullen J, Rostron T, Corbett K, Aiyer S, Butler K, Smith R, Banatvala JF: Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J Med Virol 1998, 54:113-117.
19. Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, Koff WC, the NIAID AIDS Vaccine Clinical Trials Network: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991, 114:119-27.
20. Kostrikis LG, Cao Y, Leu J, Qin L, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996, 70:427-44.
21. Homsy J, Meyer M, Levy JA: Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 1990, 64:1437-40.
22. Homsy J, Tateno M, Levy JA: Antibody-dependent enhancement of HIV infection [letter]. Lancet 1998, 1:1285-86.
23. Montefiori DC, Graham BS, Kliks S, Wright PF, the NIAID AIDS Vaccine Clinical Trials Network: Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J Clin Immunol 1992, 12:429-39.
24. Robinson WE Jr, Montefiori DC, Mitchell WM: Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988, 1:790-4.
25. Takeda A, Tuazon CU, Ennis FA: Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988, 242:580-2.
26. Toth FD, Mosborg-Ptersen P, Kis J, Aboagye-Mathiesen G, Zdravkovic M, Hager H, Aranyosi J, Lampe L, Ebbesen P: Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol 1994, 96:389-394.
27. Pancino G, Leste-Lasserre T, Burgard M, Costagliola D, Ivanoff S, Blanche S, Rouzioux C, Sonigo P: Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. J Infect Dis 1998, 177:1737-1741.
28. Mann DL, Hamlin-Green G, Willoughby A, Landesman SH, Goedert JJ: Immunoglobulin class and subclass antibodies to HIV proteins in maternal serum: Association with perinatal transmission. J AIDS 1994, 7:617-622.
29. Gras G, Beyssen V, Tranchot-Diallo J, Parnet-Mathieu F, Lasfargues G, Courpotin C, Dormont D: Neutralizing antibodies and complement-mediated, antibody-dependent enhancement (C'-ADE) of human immunodeficiency virus infection in its vertical transmission. AJRI 1998, 39:381-386.
30. Dickover RE, Garratty EM, Herman SA, Sim M, Plaeger S, Boyer PJ, Keller M, Deveikis A, Stiehm ER, Bryson YJ: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA 1996, 275:599-605.
31. Mayaux MJ, Dussaix E, Isopet J, Rekacewicz C, Mandelbrot L, Ciraru-Vigneron N, Allemon MC, Chambrin V, Katlama C, Delfraissy JF, Puel J: Maternal viral load during pregnancy and maternal-to-child transmission of human immunodeficiency virus type1: The French perinatal cohort studies. J Infect Dis 1997, 175:172-5.
32. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, OSullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, Sullivan JL: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. New Eng J Med 1996, 336:1621-1629.
33. Shaffer N, Roongpipong A, Siriwasin W, Chotpltayasunondh T, Chearskul S, Young NL, Parekh B, Mock PA, Bhadrakom P, Kalish ML, Phillips SK, Grenade TC, Subbarao S, Weniger BG, Mastro TD: Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 1999, 179:590-599.
34. Garcia PM, Kalish LA, Pitt J, Minoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorilla C, Lew JF, for the Women and Infants Transmission Study Group: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. New Eng J Med 1999, 341:394-402.
35. Ioannidis JPA, Abrams EJ, Ammann A, Bulterys M, Goeder JJ, Gray L, Korber BT, Mayaux MJ, Mofenson LM, Newell ML, Shapiro DE, Teglas JP, Wilfert CM: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Inf Dis 2001, 183:539-45.
36. Mazza C, Ravaggi A, Rodella A, Duse M, Padula D, Lomini M, Castell F, Bresciami S, Albertini A, Cariani E: Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type-1 (HIV-1). Study group of vertical transmission. J Med Virol 1999, 58:59-62.
37. Melendez-Guerrero LM, Arroyo MA, Vega ME, Jimenez E, Hillyer GV, Cadilla CL: Characterization of HIV isolates from Puerto Rican maternal-infant pairs reveal predominance of non-syncytium inducing (NSI) variants with CCr5 genotype. Cell Mol Biol 2001, 147:OL39-OL47.
38. NIH: Clinical Trial: A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT). [http://clinicaltrials.gov/ct/show/NCT00000751?order=1]. Jan 4, 2005
39. NIH: Clinical Trial: A Phase I Trial to Evaluate Didanosine (ddI) in HIV-infected Pregnant Women. [http://clinicaltrials.gov/ct/show/NCT00000839? order=1]. Jan 4, 2005
40. NIH: Clinical Trial: A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers. [http://clinicaltrials.gov/ct/show/NCT00000808?order=1]. Jan 4, 2005
41. NIH: Clinical Trial: Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells. [http://clinicaltrials.gov/ct/show/NCT00000830?order=1]. Jan 4, 2005
42. NIH: Clinical Trial: A Study of Nevirapine for the Prevention of HIV Transmission from Mothers to Their Babies. [http://clinicaltrials.gov/ct/show/ NCT00000869?order=1]. Jan 4, 2005
43. NIH: Clinical Trial: A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women. [http://clinicaltrials.gov/ct/show/NCT00000862? order=1]. Jan 4, 2005
44. NIH: Clinical Trial: A Study to Evaluate the Safety and Tolerance of Stravudine (d4T) in Combination with Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants. [http://clinicaltrials.gov/ct/show/NCT00000878?order=1] . Jan 4, 2005
45. Centers for Disease Control (CDC): 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:RR-1.
46. Contopoulos-Ioannidis DG, Ioannidis JPA: Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission. A meta-analysis. J AIDS Human Retrovirol 1998, 18:126-35.
47. O'Shea S, de Ruiter A, Mullen J, Cobett K, Chrystie IL, Newell ML, Banatvala JE: Quantification of HIV-1 RNA in cervico-vaginal secretions: An improved method of sample collection. AIDS 1997, 11:1056-57.
48. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996, 173:60-7.
49. Jolly PE, Weiss HL: Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates. Virology 2000, 273:52-59.
50. Halstead SB: Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239:476-481.
51. Vennema H, de Groot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, Spaan WJ: Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990, 64:1407-1409.
52. Melendez-Guerrero LM, Holmes R, Backe E, Poliotti B, Ibegbu C, Lee F, Panigel M, Schwartz D, Huddleston J, Nahmias A: In vitro infection of Hofbauer cell with a monocytotropic strain of HIV-1. Trophoblast Research 1994, 8:33-45.
53. Plaud-Valentin M, Delgado R, Garcia V, Zorilla C, Gandia J, Melendez-Guerrero LM: HIV infection of placental macrophages: effect on the secretion of HIV stimulatory cytokines. Cell Mol Biol 1999, 45:423-31.
54. Valentin A, Albert J, Fenyo EM, Asjo B: Dual Tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J Virol 1994, 68:6684-6689.
55. Department of Health and Human Services: ACTG Virology Manual for HIV Laboratories. Department of Health and Human Services, Division of AIDS, National Institutes of Allergy and Infectious Diseases, NIH Publication No. 94 3828 1994.
56. Wolinsky S, Wike C, Korber B, Hutto C, Praks W, Rosemblum L, Kunstman-Furtado KM, Munoz JL: Selective transmission of human immunodeficiency virus type-1 variants from mother to infants. Science 1992, 255:1134-1137.
57. Jolly PE: Replicative characteristics of primary isolates of the human immunodeficiency virus type 1 in peripheral blood mononuclear cells, primary macrophages, and CD4+ transformed T-cell lines. Cell Mol Biol 1997, 43:1057-65.
58. Rouzioux C, Costaglioloa D, Burgard M: Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. Am J Epidemiol 1996, 142:1330-1337.